Review



fluorescence in vivo imaging system fobi  (NeoScience Co Ltd)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    NeoScience Co Ltd fluorescence in vivo imaging system fobi
    Fluorescence In Vivo Imaging System Fobi, supplied by NeoScience Co Ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/fluorescence in vivo imaging system fobi/product/NeoScience Co Ltd
    Average 90 stars, based on 1 article reviews
    fluorescence in vivo imaging system fobi - by Bioz Stars, 2026-02
    90/100 stars

    Images



    Similar Products

    fluorescence in vivo imaging system fobi  (NeoScience Co Ltd)
    90
    NeoScience Co Ltd fluorescence in vivo imaging system fobi
    Fluorescence In Vivo Imaging System Fobi, supplied by NeoScience Co Ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/fluorescence in vivo imaging system fobi/product/NeoScience Co Ltd
    Average 90 stars, based on 1 article reviews
    fluorescence in vivo imaging system fobi - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier
    fluorescence in vivo imaging system  (Cellgentek)
    95
    Cellgentek fluorescence in vivo imaging system
    Fluorescence In Vivo Imaging System, supplied by Cellgentek, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/fluorescence in vivo imaging system/product/Cellgentek
    Average 95 stars, based on 1 article reviews
    fluorescence in vivo imaging system - by Bioz Stars, 2026-02
    95/100 stars
    		  Buy from Supplier
    fluorescence imaging system  (Cellgentek)
    95
    Cellgentek fluorescence imaging system
    Fluorescence Imaging System, supplied by Cellgentek, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/fluorescence imaging system/product/Cellgentek
    Average 95 stars, based on 1 article reviews
    fluorescence imaging system - by Bioz Stars, 2026-02
    95/100 stars
    		  Buy from Supplier
    fobi fluorescence imaging system  (Cellgentek)
    95
    Cellgentek fobi fluorescence imaging system
    Fobi Fluorescence Imaging System, supplied by Cellgentek, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/fobi fluorescence imaging system/product/Cellgentek
    Average 95 stars, based on 1 article reviews
    fobi fluorescence imaging system - by Bioz Stars, 2026-02
    95/100 stars
    		  Buy from Supplier
    precision fluorescence analyzer  (Cellgentek)
    95
    Cellgentek precision fluorescence analyzer
    In vitro, cathepsin B cleavage, cellular toxicity and <t>fluorescence</t> imaging of (Ac)FRRF-DTX NPs. HPLC analysis of (Ac)FRRF-DTX NPs incubated without ( a ) or with ( b ) enzyme reaction buffer containing cathepsin B for different time points (0–72 h). ( c ) LC-MS analysis of PTXm during the cathepsin B cleavage experiment. ( d ) The assessment of cathepsin B activity levels in HDFa, Hep G2, CT26.wt, and A549 cell lines ( n = 3). ( e ) Evaluation of anticancer efficacy on Hep G2 cells treated with DTX, PTX, PTXm, (Ac)FRRF, (Ac)FRRF-DTX NPs and de-Boc-DTX ( n = 5 − 6). ( f ) Cellular uptake of RITC-PTX and RITC-(Ac)FRRF-DTX NPs in Hep G2 cells (Scale bar = 50 μm). ( g ) Data quantifying the fluorescence intensity over time of (Ac)FRRF-DTX NPs and PTX ( n = 3). ( h ) Fluorescent microscopy imaging observing cell death in Hep G2 cells treated with PTX, PTXm and (Ac)FRRF-DTX NPs (Scale bar = 50 μm). ( i ) Quantification of fluorescence intensity from nucleic acid staining using ImageJ software ( n = 5). ( j ) microtubule binding of PTX, PTXm and (Ac)FRRF-DTX NPs (Scale bar = 50 μm). ( k ) Quantification of fluorescence intensity from Microtubule Cytoskeleton Dye using ImageJ software ( n = 5). ( l ) Confocal images of (Ac)FRRF-DTX NPs (Scale bar = 10 μm). *p < 0.05, **p < 0.01 and ***p < 0.001
    Precision Fluorescence Analyzer, supplied by Cellgentek, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/precision fluorescence analyzer/product/Cellgentek
    Average 95 stars, based on 1 article reviews
    precision fluorescence analyzer - by Bioz Stars, 2026-02
    95/100 stars
    		  Buy from Supplier
    fluorescence intensity  (Cellgentek)
    95
    Cellgentek fluorescence intensity
    In vitro, cathepsin B cleavage, cellular toxicity and <t>fluorescence</t> imaging of (Ac)FRRF-DTX NPs. HPLC analysis of (Ac)FRRF-DTX NPs incubated without ( a ) or with ( b ) enzyme reaction buffer containing cathepsin B for different time points (0–72 h). ( c ) LC-MS analysis of PTXm during the cathepsin B cleavage experiment. ( d ) The assessment of cathepsin B activity levels in HDFa, Hep G2, CT26.wt, and A549 cell lines ( n = 3). ( e ) Evaluation of anticancer efficacy on Hep G2 cells treated with DTX, PTX, PTXm, (Ac)FRRF, (Ac)FRRF-DTX NPs and de-Boc-DTX ( n = 5 − 6). ( f ) Cellular uptake of RITC-PTX and RITC-(Ac)FRRF-DTX NPs in Hep G2 cells (Scale bar = 50 μm). ( g ) Data quantifying the fluorescence intensity over time of (Ac)FRRF-DTX NPs and PTX ( n = 3). ( h ) Fluorescent microscopy imaging observing cell death in Hep G2 cells treated with PTX, PTXm and (Ac)FRRF-DTX NPs (Scale bar = 50 μm). ( i ) Quantification of fluorescence intensity from nucleic acid staining using ImageJ software ( n = 5). ( j ) microtubule binding of PTX, PTXm and (Ac)FRRF-DTX NPs (Scale bar = 50 μm). ( k ) Quantification of fluorescence intensity from Microtubule Cytoskeleton Dye using ImageJ software ( n = 5). ( l ) Confocal images of (Ac)FRRF-DTX NPs (Scale bar = 10 μm). *p < 0.05, **p < 0.01 and ***p < 0.001
    Fluorescence Intensity, supplied by Cellgentek, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/fluorescence intensity/product/Cellgentek
    Average 95 stars, based on 1 article reviews
    fluorescence intensity - by Bioz Stars, 2026-02
    95/100 stars
    		  Buy from Supplier
    fobi fluorescent in vivo imaging system  (Cellgentek)
    95
    Cellgentek fobi fluorescent in vivo imaging system
    In vitro, cathepsin B cleavage, cellular toxicity and <t>fluorescence</t> imaging of (Ac)FRRF-DTX NPs. HPLC analysis of (Ac)FRRF-DTX NPs incubated without ( a ) or with ( b ) enzyme reaction buffer containing cathepsin B for different time points (0–72 h). ( c ) LC-MS analysis of PTXm during the cathepsin B cleavage experiment. ( d ) The assessment of cathepsin B activity levels in HDFa, Hep G2, CT26.wt, and A549 cell lines ( n = 3). ( e ) Evaluation of anticancer efficacy on Hep G2 cells treated with DTX, PTX, PTXm, (Ac)FRRF, (Ac)FRRF-DTX NPs and de-Boc-DTX ( n = 5 − 6). ( f ) Cellular uptake of RITC-PTX and RITC-(Ac)FRRF-DTX NPs in Hep G2 cells (Scale bar = 50 μm). ( g ) Data quantifying the fluorescence intensity over time of (Ac)FRRF-DTX NPs and PTX ( n = 3). ( h ) Fluorescent microscopy imaging observing cell death in Hep G2 cells treated with PTX, PTXm and (Ac)FRRF-DTX NPs (Scale bar = 50 μm). ( i ) Quantification of fluorescence intensity from nucleic acid staining using ImageJ software ( n = 5). ( j ) microtubule binding of PTX, PTXm and (Ac)FRRF-DTX NPs (Scale bar = 50 μm). ( k ) Quantification of fluorescence intensity from Microtubule Cytoskeleton Dye using ImageJ software ( n = 5). ( l ) Confocal images of (Ac)FRRF-DTX NPs (Scale bar = 10 μm). *p < 0.05, **p < 0.01 and ***p < 0.001
    Fobi Fluorescent In Vivo Imaging System, supplied by Cellgentek, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/fobi fluorescent in vivo imaging system/product/Cellgentek
    Average 95 stars, based on 1 article reviews
    fobi fluorescent in vivo imaging system - by Bioz Stars, 2026-02
    95/100 stars
    		  Buy from Supplier

    Image Search Results


    In vitro, cathepsin B cleavage, cellular toxicity and fluorescence imaging of (Ac)FRRF-DTX NPs. HPLC analysis of (Ac)FRRF-DTX NPs incubated without ( a ) or with ( b ) enzyme reaction buffer containing cathepsin B for different time points (0–72 h). ( c ) LC-MS analysis of PTXm during the cathepsin B cleavage experiment. ( d ) The assessment of cathepsin B activity levels in HDFa, Hep G2, CT26.wt, and A549 cell lines ( n = 3). ( e ) Evaluation of anticancer efficacy on Hep G2 cells treated with DTX, PTX, PTXm, (Ac)FRRF, (Ac)FRRF-DTX NPs and de-Boc-DTX ( n = 5 − 6). ( f ) Cellular uptake of RITC-PTX and RITC-(Ac)FRRF-DTX NPs in Hep G2 cells (Scale bar = 50 μm). ( g ) Data quantifying the fluorescence intensity over time of (Ac)FRRF-DTX NPs and PTX ( n = 3). ( h ) Fluorescent microscopy imaging observing cell death in Hep G2 cells treated with PTX, PTXm and (Ac)FRRF-DTX NPs (Scale bar = 50 μm). ( i ) Quantification of fluorescence intensity from nucleic acid staining using ImageJ software ( n = 5). ( j ) microtubule binding of PTX, PTXm and (Ac)FRRF-DTX NPs (Scale bar = 50 μm). ( k ) Quantification of fluorescence intensity from Microtubule Cytoskeleton Dye using ImageJ software ( n = 5). ( l ) Confocal images of (Ac)FRRF-DTX NPs (Scale bar = 10 μm). *p < 0.05, **p < 0.01 and ***p < 0.001

    Journal: Nano Convergence

    Article Title: Tumor-specific biochemical nanoconversion of self-assembled peptide-conjugated paclitaxel-docetaxel-based nanoparticles

    doi: 10.1186/s40580-025-00487-0

    Figure Lengend Snippet: In vitro, cathepsin B cleavage, cellular toxicity and fluorescence imaging of (Ac)FRRF-DTX NPs. HPLC analysis of (Ac)FRRF-DTX NPs incubated without ( a ) or with ( b ) enzyme reaction buffer containing cathepsin B for different time points (0–72 h). ( c ) LC-MS analysis of PTXm during the cathepsin B cleavage experiment. ( d ) The assessment of cathepsin B activity levels in HDFa, Hep G2, CT26.wt, and A549 cell lines ( n = 3). ( e ) Evaluation of anticancer efficacy on Hep G2 cells treated with DTX, PTX, PTXm, (Ac)FRRF, (Ac)FRRF-DTX NPs and de-Boc-DTX ( n = 5 − 6). ( f ) Cellular uptake of RITC-PTX and RITC-(Ac)FRRF-DTX NPs in Hep G2 cells (Scale bar = 50 μm). ( g ) Data quantifying the fluorescence intensity over time of (Ac)FRRF-DTX NPs and PTX ( n = 3). ( h ) Fluorescent microscopy imaging observing cell death in Hep G2 cells treated with PTX, PTXm and (Ac)FRRF-DTX NPs (Scale bar = 50 μm). ( i ) Quantification of fluorescence intensity from nucleic acid staining using ImageJ software ( n = 5). ( j ) microtubule binding of PTX, PTXm and (Ac)FRRF-DTX NPs (Scale bar = 50 μm). ( k ) Quantification of fluorescence intensity from Microtubule Cytoskeleton Dye using ImageJ software ( n = 5). ( l ) Confocal images of (Ac)FRRF-DTX NPs (Scale bar = 10 μm). *p < 0.05, **p < 0.01 and ***p < 0.001

    Article Snippet: Also, the fluorescence intensity in nude mice was captured using a precision fluorescence analyzer (FOBI, CELLGENTEK, Republic of Korea).

    Techniques: In Vitro, Fluorescence, Imaging, Incubation, Liquid Chromatography with Mass Spectroscopy, Activity Assay, Microscopy, Staining, Software, Binding Assay

    In vivo biodistribution and retention level in the bloodstream of (Ac)FRRF-DTX NPs. ( a ) Scheme describing the in vivo distribution study of (Ac)FRRF-DTX NPs using BALB/c nude mice. ( b ) In vivo distribution over time of RITC-(Ac)FRRF-DTX NPs administered via tail vein injection in BALB/c nude mice. ( c ) Quantified graphs depicting fluorescent intensity in tumor regions ( n = 3). Images showing the measurement of fluorescence intensity from hourly extractions of organs and tumors in mice treated with RITC-(Ac)FRRF-DTX NPs ( d ) and treated with RITC-de-Boc-DTX ( e ). ( f ) Quantified graphs depicting fluorescent intensity in tumor tissues over time ( n = 3). ( g ) The concentration in the bloodstream of Sprague-Dawley rats treated with RITC-(Ac)FRRF-DTX NPs and RITC-de-Boc-DTX administered via tail vein injection ( n = 3). The AUC (h) and half-life (i) ( n = 3). *p < 0.05, **p < 0.01 and ***p < 0.001

    Journal: Nano Convergence

    Article Title: Tumor-specific biochemical nanoconversion of self-assembled peptide-conjugated paclitaxel-docetaxel-based nanoparticles

    doi: 10.1186/s40580-025-00487-0

    Figure Lengend Snippet: In vivo biodistribution and retention level in the bloodstream of (Ac)FRRF-DTX NPs. ( a ) Scheme describing the in vivo distribution study of (Ac)FRRF-DTX NPs using BALB/c nude mice. ( b ) In vivo distribution over time of RITC-(Ac)FRRF-DTX NPs administered via tail vein injection in BALB/c nude mice. ( c ) Quantified graphs depicting fluorescent intensity in tumor regions ( n = 3). Images showing the measurement of fluorescence intensity from hourly extractions of organs and tumors in mice treated with RITC-(Ac)FRRF-DTX NPs ( d ) and treated with RITC-de-Boc-DTX ( e ). ( f ) Quantified graphs depicting fluorescent intensity in tumor tissues over time ( n = 3). ( g ) The concentration in the bloodstream of Sprague-Dawley rats treated with RITC-(Ac)FRRF-DTX NPs and RITC-de-Boc-DTX administered via tail vein injection ( n = 3). The AUC (h) and half-life (i) ( n = 3). *p < 0.05, **p < 0.01 and ***p < 0.001

    Article Snippet: Also, the fluorescence intensity in nude mice was captured using a precision fluorescence analyzer (FOBI, CELLGENTEK, Republic of Korea).

    Techniques: In Vivo, Injection, Fluorescence, Concentration Assay

    In vitro, cathepsin B cleavage, cellular toxicity and fluorescence imaging of (Ac)FRRF-DTX NPs. HPLC analysis of (Ac)FRRF-DTX NPs incubated without ( a ) or with ( b ) enzyme reaction buffer containing cathepsin B for different time points (0–72 h). ( c ) LC-MS analysis of PTXm during the cathepsin B cleavage experiment. ( d ) The assessment of cathepsin B activity levels in HDFa, Hep G2, CT26.wt, and A549 cell lines ( n = 3). ( e ) Evaluation of anticancer efficacy on Hep G2 cells treated with DTX, PTX, PTXm, (Ac)FRRF, (Ac)FRRF-DTX NPs and de-Boc-DTX ( n = 5 − 6). ( f ) Cellular uptake of RITC-PTX and RITC-(Ac)FRRF-DTX NPs in Hep G2 cells (Scale bar = 50 μm). ( g ) Data quantifying the fluorescence intensity over time of (Ac)FRRF-DTX NPs and PTX ( n = 3). ( h ) Fluorescent microscopy imaging observing cell death in Hep G2 cells treated with PTX, PTXm and (Ac)FRRF-DTX NPs (Scale bar = 50 μm). ( i ) Quantification of fluorescence intensity from nucleic acid staining using ImageJ software ( n = 5). ( j ) microtubule binding of PTX, PTXm and (Ac)FRRF-DTX NPs (Scale bar = 50 μm). ( k ) Quantification of fluorescence intensity from Microtubule Cytoskeleton Dye using ImageJ software ( n = 5). ( l ) Confocal images of (Ac)FRRF-DTX NPs (Scale bar = 10 μm). *p < 0.05, **p < 0.01 and ***p < 0.001

    Journal: Nano Convergence

    Article Title: Tumor-specific biochemical nanoconversion of self-assembled peptide-conjugated paclitaxel-docetaxel-based nanoparticles

    doi: 10.1186/s40580-025-00487-0

    Figure Lengend Snippet: In vitro, cathepsin B cleavage, cellular toxicity and fluorescence imaging of (Ac)FRRF-DTX NPs. HPLC analysis of (Ac)FRRF-DTX NPs incubated without ( a ) or with ( b ) enzyme reaction buffer containing cathepsin B for different time points (0–72 h). ( c ) LC-MS analysis of PTXm during the cathepsin B cleavage experiment. ( d ) The assessment of cathepsin B activity levels in HDFa, Hep G2, CT26.wt, and A549 cell lines ( n = 3). ( e ) Evaluation of anticancer efficacy on Hep G2 cells treated with DTX, PTX, PTXm, (Ac)FRRF, (Ac)FRRF-DTX NPs and de-Boc-DTX ( n = 5 − 6). ( f ) Cellular uptake of RITC-PTX and RITC-(Ac)FRRF-DTX NPs in Hep G2 cells (Scale bar = 50 μm). ( g ) Data quantifying the fluorescence intensity over time of (Ac)FRRF-DTX NPs and PTX ( n = 3). ( h ) Fluorescent microscopy imaging observing cell death in Hep G2 cells treated with PTX, PTXm and (Ac)FRRF-DTX NPs (Scale bar = 50 μm). ( i ) Quantification of fluorescence intensity from nucleic acid staining using ImageJ software ( n = 5). ( j ) microtubule binding of PTX, PTXm and (Ac)FRRF-DTX NPs (Scale bar = 50 μm). ( k ) Quantification of fluorescence intensity from Microtubule Cytoskeleton Dye using ImageJ software ( n = 5). ( l ) Confocal images of (Ac)FRRF-DTX NPs (Scale bar = 10 μm). *p < 0.05, **p < 0.01 and ***p < 0.001

    Article Snippet: The fluorescence intensity of RITC-(Ac)FRRF-DTX was measured and quantified using a precision fluorescence analyzer (FOBI, CELLGENTEK, Republic of Korea) at various time points after intravenous injection (0, 0.5, 1, 3, 6, 12, 24 and 48 h).

    Techniques: In Vitro, Fluorescence, Imaging, Incubation, Liquid Chromatography with Mass Spectroscopy, Activity Assay, Microscopy, Staining, Software, Binding Assay

    In vivo biodistribution and retention level in the bloodstream of (Ac)FRRF-DTX NPs. ( a ) Scheme describing the in vivo distribution study of (Ac)FRRF-DTX NPs using BALB/c nude mice. ( b ) In vivo distribution over time of RITC-(Ac)FRRF-DTX NPs administered via tail vein injection in BALB/c nude mice. ( c ) Quantified graphs depicting fluorescent intensity in tumor regions ( n = 3). Images showing the measurement of fluorescence intensity from hourly extractions of organs and tumors in mice treated with RITC-(Ac)FRRF-DTX NPs ( d ) and treated with RITC-de-Boc-DTX ( e ). ( f ) Quantified graphs depicting fluorescent intensity in tumor tissues over time ( n = 3). ( g ) The concentration in the bloodstream of Sprague-Dawley rats treated with RITC-(Ac)FRRF-DTX NPs and RITC-de-Boc-DTX administered via tail vein injection ( n = 3). The AUC (h) and half-life (i) ( n = 3). *p < 0.05, **p < 0.01 and ***p < 0.001

    Journal: Nano Convergence

    Article Title: Tumor-specific biochemical nanoconversion of self-assembled peptide-conjugated paclitaxel-docetaxel-based nanoparticles

    doi: 10.1186/s40580-025-00487-0

    Figure Lengend Snippet: In vivo biodistribution and retention level in the bloodstream of (Ac)FRRF-DTX NPs. ( a ) Scheme describing the in vivo distribution study of (Ac)FRRF-DTX NPs using BALB/c nude mice. ( b ) In vivo distribution over time of RITC-(Ac)FRRF-DTX NPs administered via tail vein injection in BALB/c nude mice. ( c ) Quantified graphs depicting fluorescent intensity in tumor regions ( n = 3). Images showing the measurement of fluorescence intensity from hourly extractions of organs and tumors in mice treated with RITC-(Ac)FRRF-DTX NPs ( d ) and treated with RITC-de-Boc-DTX ( e ). ( f ) Quantified graphs depicting fluorescent intensity in tumor tissues over time ( n = 3). ( g ) The concentration in the bloodstream of Sprague-Dawley rats treated with RITC-(Ac)FRRF-DTX NPs and RITC-de-Boc-DTX administered via tail vein injection ( n = 3). The AUC (h) and half-life (i) ( n = 3). *p < 0.05, **p < 0.01 and ***p < 0.001

    Article Snippet: The fluorescence intensity of RITC-(Ac)FRRF-DTX was measured and quantified using a precision fluorescence analyzer (FOBI, CELLGENTEK, Republic of Korea) at various time points after intravenous injection (0, 0.5, 1, 3, 6, 12, 24 and 48 h).

    Techniques: In Vivo, Injection, Fluorescence, Concentration Assay